Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03MTN
|
|||
| Former ID |
DCL000561
|
|||
| Drug Name |
Mepolizumab
|
|||
| Synonyms |
Bosatria; Scoparianoside C; SB 240563; Immunoglobulin G1, anti-(human interleukin 5) (human-mouse monoclonal SB-240563 gamma1-chain), disulfide with human-mouse monoclonal SB-240563 kappa-chain, dimer; (2S,3S,4S,5R,6R)-6-[[(3S,4aR,6aR,6bS,8aS,14aR,14bR)-8a-carboxy-4,4,6a,6b,11,11,14b-heptamethyl-1,2,3,4a,5,6,7,8,9,10,12,13,14,14a-tetradecahydropicen-3-yl]oxy]-3,5-dihydroxy-4-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxyoxane-2-carboxylic acid
Click to Show/Hide
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Severe asthma [ICD-11: CA23; ICD-10: J45, J45.8] | Approved | [1], [2] | |
| Asthma [ICD-11: CA23; ICD-10: J45, J45.8] | Phase 2/3 | [3], [4], [5], [6], [7], [8], [9], [10], [11], [12], [13], [14], [15], [16], [17], [18], [19], [20], [21], [22], [23], [24] | ||
| Company |
MedImmune
|
|||
| ADReCS Drug ID | BADD_D01389 | |||
| SuperDrug ATC ID |
L04AC06
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7685). | |||
| REF 2 | Emerging drugs for asthma. Expert Opin Emerg Drugs. 2008 Dec;13(4):643-53. | |||
| REF 3 | ClinicalTrials.gov (NCT01366521) Dose Ranging Pharmacokinetics and Pharmacodynamics Study With Mepolizumab in Asthma Patients With Elevated Eosinophils | |||
| REF 4 | ClinicalTrials.gov (NCT01842607) A Study to Determine Long-term Safety of Mepolizumab in Asthmatic Subjects | |||
| REF 5 | ClinicalTrials.gov (NCT00358449) Intravenous Mepolizumab In Children With Eosinophilic Esophagitis | |||
| REF 6 | ClinicalTrials.gov (NCT02377427) Pharmacokinetics and Pharmacodynamics of Mepolizumab Administered Subcutaneously in Children | |||
| REF 7 | ClinicalTrials.gov (NCT00086658) Intravenous Mepolizumab In Subjects With Hypereosinophilic Syndromes (HES) | |||
| REF 8 | ClinicalTrials.gov (NCT00716651) Safety and Efficacy Study of Mepolizumab in Churg Strauss Syndrome | |||
| REF 9 | ClinicalTrials.gov (NCT00274703) An Evaluation Of Mepolizumab In Therapy Of Eosinophilic Oesophagitis In Adult Patients | |||
| REF 10 | ClinicalTrials.gov (NCT01691859) MEA112997 Open-label Long Term Extension Safety Study of Mepolizumab in Asthmatic Subjects | |||
| REF 11 | ClinicalTrials.gov (NCT03021304) Study of Mepolizumab Safety Syringe in Asthmatics | |||
| REF 12 | ClinicalTrials.gov (NCT03099096) Study of Mepolizumab Autoinjector in Asthmatics | |||
| REF 13 | ClinicalTrials.gov (NCT00097370) Open-Label Extension Of Intravenous Mepolizumab In Patients With Hypereosinophilic Syndrome | |||
| REF 14 | ClinicalTrials.gov (NCT03055195) Efficacy and Safety Study of Mepolizumab in Subjects With Moderate to Severe Atopic Dermatitis | |||
| REF 15 | ClinicalTrials.gov (NCT02836496) Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES) | |||
| REF 16 | ClinicalTrials.gov (NCT01691521) Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Subjects With Severe Uncontrolled Refractory Asthma | |||
| REF 17 | ClinicalTrials.gov (NCT02105948) Study to Evaluate Efficacy and Safety of Mepolizumab for Frequently Exacerbating Chronic Obstructive Pulmonary Disease (COPD) Patients | |||
| REF 18 | ClinicalTrials.gov (NCT02105961) Efficacy and Safety of Mepolizumab as an Add-on Treatment in Chronic Obstructive Pulmonary Disease (COPD) | |||
| REF 19 | ClinicalTrials.gov (NCT02594332) Effects of Mepolizumab Compared to Placebo on Airway Physiology in Patients With Eosinophilic Asthma: MEMORY Study | |||
| REF 20 | ClinicalTrials.gov (NCT01520051) Mepolizumab Treatment for Rhinovirus-induced Asthma Exacerbations | |||
| REF 21 | ClinicalTrials.gov (NCT01463644) Mepolizumab in Chronic Obstructive Pulmonary Diseases (COPD) With Eosinophilic Bronchitis | |||
| REF 22 | ClinicalTrials.gov (NCT03085797) Effect of Mepolizumab in Severe Bilateral Nasal Polyps | |||
| REF 23 | ClinicalTrials.gov (NCT01691508) Mepolizumab Steroid-Sparing Study in Subjects With Severe Refractory Asthma | |||
| REF 24 | ClinicalTrials.gov (NCT01362244) Mepolizumab in Nasal Polyposis | |||
| REF 25 | Mepolizumab: 240563, anti-IL-5 monoclonal antibody - GlaxoSmithKline, anti-interleukin-5 monoclonal antibody - GlaxoSmithKline, SB 240563. Drugs R D. 2008;9(2):125-30. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.